Table 1.
Summary of Studies of COVID-19 in Patients With Cancer
| Ref | Patient Population | Geographic Location | Study Design | Clinical Severity (%) | COVID-19 Treatment (%) | Outcomes (%) |
|---|---|---|---|---|---|---|
| All cancer | ||||||
| [14] | 1590 COVID-19 patients, 18 with cancer • 28% lung, 22% colorectal, 17% breast, 11% bladder |
China (national) | Retrospective cohort | n/a | n/a | ICU or death (39) |
| [15] | 1524 cancer patients, 12 with COVID-19 • 58% lung, 8% rectal, 8% colon, 8% breast, 8% bladder • 42% active treatment |
China (Wuhan) | Retrospective cohort | Hospitalized (100), ICU (8) | n/a | Recovered (50), died (25) |
| [16] | 1276 cancer patients, 28 with COVID-19 • 25% lung, 14% esophageal, 11% breast • 36% stage IV disease • 21% active treatment) |
China (Wuhan) | Retrospective cohort | Hospitalized (100), ICU (21), intubated (8) | Antivirals (71), IVIG (36), steroids (54) | Recovered (36), died (29) |
| [17] | 5688 COVID-19 patients, 334 with cancer |
United States (NY) | Retrospective cohort | Intubated (11) | n/a | Died (11) |
| [10] | 105 cancer patients with COVID-19 • 21% lung, 12% GI, 10% breast, 10% thyroid, 9% blood • 14% chemotherapy within 40 days |
China (Wuhan) | Case-control | Hospitalized (100), ICU (19), intubated (10) | n/a | Died (11) |
| [11] | • 218 cancer patients with COVID-19 75% solid tumor, 25% HM | United States (NY) | Case-control | n/a | n/a | Died (28) |
| [12] | 1575 patients with COVID-19, 52 with cancer • 19% lung, 17% breast, 10% colon, 8% cervical • 19% cancer therapy within 1 month |
China (Wuhan) | Case-control | Intubated (0) | Antivirals (100), IVIG (25), steroids (31) | Recovered (79), died (21) |
| [13] | 13 077 patients with COVID-19, 232 with cancer | China (Wuhan) | Retrospective cohort | Hospitalized (10), intubated (9) | Antivirals (79), immunomodulator (37) | Died (20) |
| [18] | 205 cancer patients with COVID-19 • 20% breast, 14% colorectal 12% lung, 11% HM • 20% cancer treatment within 4 weeks |
China (Wuhan) | Retrospective cohort | ICU (15), intubated (10) | Antivirals (94), IVIG (29), steroids (30) | Died (20) |
| [19] | 928 cancer patients with COVID-19 • 20% breast, 16% prostate, 22% HM • 39% active cancer therapy |
United States, Canada, Spain | Registry/retrospective cohort | Hospitalized (40), ICU (17), intubated (13) | Antivirals (30) | Died (13) |
| [20] | 800 cancer patients with COVID-19 • 22% HM, 19% GI, 13% breast • 35% cancer treatment within 4 weeks |
United Kingdom | Registry/prospective cohort | Hospitalized (88), ICU (7) | n/a | Died (23) |
| Hematologic malignancy | ||||||
| [21] | 128 HM patients, 13 with COVID-19 | China (Wuhan) | Retrospective cohort | Hospitalized (100), intubated (8) | Antivirals (>53a), steroids (27) | Recovered (47), died (53) |
| [22] | 6 Waldenstrom’s macroglobulinemia patients on BTKi with COVID-19 | United States (MA) | Case series | Hospitalized (17) | Antivirals (33), tocilizumab (17) | Recovered (67), died (0) |
| [23] | 34 HM patients with known/suspected COVID-19 | Spain | Retrospective cohort | ICU (6) | Antivirals (>85a), tocilizumab (24), steroids (50) | Died (32) |
| [24] | 25 HM patients with COVID-19 • 28% SCT, 56% active therapy |
France | Case series | Intubated (24) | Antivirals (20) Immunomodulators (16) Steroids (16) |
Died (40) |
| [25] | 7 MGUS patients with COVID-19 | United States (NY) | Case series | Hospitalized (71), ICU (0), intubated (0) | Antivirals (29) | Recovered (86), died (14) |
| [26] | 35 HM patients with COVID-19 • 69% active therapy |
United Kingdom | Retrospective cohort | n/a | n/a | Died (40) |
| [27] | 7 SCT recipients with COVID-19 • 86% allogeneic |
United Kingdom | Case series | n/a | n/a | Died (43) |
| [28] | 236 SCT recipients, 5 with COVID-19 | Italy | Survey | n/a | n/a | n/a |
| [29] | 530 CML patients, 5 with COVID-19 | China | Survey | n/a | n/a | Recovered (80), died (20) |
| [30] | 7 MM patients with COVID-19 | United States (WI) | Retrospective cohort | Hospitalized (71), ICU (57), intubated (14) | Antivirals (43), tocilizumab (0) | Recovered (43), died (57) |
| [31] | 8 CLL patients on BTKi with COVID-19 | United States (NY) | Case series | Hospitalized (10), intubated (0) | … | Died (25) |
Studies with ≥5 patients included.
Abbreviations: COVID-19, coronavirus disease 2019; GI, gastrointestinal; HM, hematologic malignancy; BTKi, Bruton tyrosine kinase inhibitor; ICU, intensive care unit; IVIG, intravenous immunoglobulin; MGUS, monoclonal gammopathy of uncertain significance; SCT, stem-cell transplant; CML, chronic myeloid leukemia; MM, multiple myeloma; n/a, not available; Ref, reference.
aAccurate estimate not available from published data, minimum % listed.